Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

被引：0

作者：

A. Luna

L. Pérez-Lamas

C. Boque

P. Giraldo

B. Xicoy

C. Ruiz Nuño

M. Moreno Vega

A. Alvarez-Larrán

A. Salamanca

A. García-Noblejas

F. Vall-Llovera

L. Villalon

N. De las Heras

E. Ramila

M. Pérez-Encinas

B. Cuevas

R. Perez-Lopez

F. Sanchez-Guijo

A. Jiménez-Velasco

S. Lakhwani

L. Felipe Casado

A. Rosell

A. Escola

M. J. Fernández

C. Garcia-Hernandez

C. Cervero

E. Mora

M. Sagüés

S. Suarez-Varela

P. Vélez

P. Carrascosa Mastell

R. F. Bitaube

L. Serrano

M. Cortes

J.A Vera Goñi

J. L. Steegmann

V. Gomez Garcia de Soria

J. M. Alonso-Dominguez

M. Colorado Araujo

A. Paz Coll

J.C Hernandez-Boluda

V. García-Gutiérrez

机构：

[1] Hospital Universitario Ramón y Cajal,Hematology Department

[2] IRYCIS,Institut Catala d’Oncologia

[3] Universidad de Alcala,Department of Medicine, University of Salamanca, Hematology Department

[4] Hospital Duran Y Reynals,undefined

[5] L’Hospitalet de Llobregat,undefined

[6] Hospital Quirón Zaragoza,undefined

[7] Institut Català d’Oncologia-Hospital Germans Trias I Pujol,undefined

[8] Hospital Regional Universitario de Málaga,undefined

[9] Hospital Doctor José Molina Orosa de Lanzarote,undefined

[10] Hospital Clinic de Barcelona,undefined

[11] Hospital de Jerez de La Frontera,undefined

[12] Hospital Universitario de La Princesa,undefined

[13] Hospital Mutua de Terrassa,undefined

[14] Hospital Universitario Fundación Alcorcón,undefined

[15] Hospital Universitario de León,undefined

[16] Hospital Parc Tauli,undefined

[17] Hospital Clínico Universitario de Santiago de Compostela,undefined

[18] Hospital Universitario de Burgos,undefined

[19] Hospital Universitario Clínico Virgen de La Arrixaca,undefined

[20] IBSAL-University Hospital of Salamanca,undefined

[21] Hospital Universitario Carlos Haya,undefined

[22] Hospital Universitario de Canarias,undefined

[23] Hospital Virgen de La Salud,undefined

[24] Hospital Virgen de La Victoria,undefined

[25] Hospital Provincial de Castellón,undefined

[26] Hospital Doctor Peset,undefined

[27] Hospital General de Alicante,undefined

[28] Hospital Virgen de La Luz,undefined

[29] Hospital Universitario Y Politécnico La Fe,undefined

[30] Hospital General de Castellón,undefined

[31] Hospital de Granollers,undefined

[32] Hospital Virgen Macarena,undefined

[33] Hospital Universitario Fundación Jiménez Díaz,undefined

[34] Hospital Universitario Marqués de Valdecilla,undefined

[35] Hospital Universitario Puerto Real,undefined

[36] Hospital Clínico Universitario-INCLIVA,undefined

[37] University of Valencia,undefined

来源：

Annals of Hematology | 2022年 / 101卷

关键词：

Leukemia; Inhibitors; Asciminib ;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US Federal Drug Administration, has demonstrated in clinical trials a good efficacy and safety profile after failure of 2GTKI. However, no study has specifically addressed response rates to asciminib in ponatinib pretreated patients (PPT). Here, we present data on responses to asciminib from 52 patients in clinical practice, 20 of them (38%) with prior ponatinib exposure. We analyzed retrospectively responses and toxicities under asciminib and compared results between PPT and non-PPT patients.

引用

页码：2263 / 2270

页数：7

共 50 条

[31] Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia
Basile, Michele
Rumi, Filippo
Cicchetti, Americo
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 87 - 95
[32] Ponatinib efficacy and safety in heavily pretreated leukemia patients (Pts) in the PACE trial at 3 years
le Coutre, P. D.
Cortes, J. E.
Kim, D. -W
Pinilla-Ibarz, J.
Paquette, R.
Chuah, C.
Nicolini, F. E.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
DeAngelo, D. J.
Abruzzese, E.
Rea, D.
Baccarani, M.
Mueller, M. C.
Gambacorti-Passerini, C.
Lustgarten, S.
Rivera, V. M.
Clackson, T.
Haluska, F. G.
Guilhot, F.
Deininger, M. W.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Kantarjian, H. M.
ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 : 182 - 183
[33] Efficacy and safety of Fremanezumab in patients with episodic and chronic migraine in a real-life setting
Gonzalez-Martinez, A.
Garcia De la Cruz, R.
Quintas, S.
Belascoain Gomez, R.
Heredia, P.
Vivancos, J.
Gago-Veiga, A.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 737 - 737
[34] High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation
Uchida, Yasuhiro
Koyama, Daisuke
Manabe, Kazuya
Suzuki, Kengo
Asano, Naomi
Endo, Mamiko
Fukatsu, Masahiko
Sano, Takahiro
Hayashi, Kiyohito
Takano, Motoki
Takahashi, Hiroshi
Kimura, Satoshi
Ikezoe, Takayuki
INTERNAL MEDICINE, 2024, 63 (05) : 717 - 720
[35] Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
Caocci, Giovanni
Mulas, Olga
Abruzzese, Elisabetta
Luciano, Luigiana
Iurlo, Alessandra
Attolico, Immacolata
Castagnetti, Fausto
Galimberti, Sara
Sgherza, Nicola
Bonifacio, Massimiliano
Annunziata, Mario
Gozzini, Antonella
Orlandi, Ester Maria
Stagno, Fabio
Binotto, Gianni
Pregno, Patrizia
Fozza, Claudio
Trawinska, Malgorzata Monika
De Gregorio, Fiorenza
Cattaneo, Daniele
Albano, Francesco
Gugliotta, Gabriele
Barate, Claudia
Scaffidi, Luigi
Elena, Chiara
Pirillo, Francesca
Scalzulli, Emilia
La Nasa, Giorgio
Foa, Robin
Breccia, Massimo
HEMATOLOGICAL ONCOLOGY, 2019, 37 (03) : 296 - 302
[36] A RETROSPECTIVE REAL-LIFE ANALYSIS OF CHRONIC MYELOID LEUKEMIA PATIENTS IN SUBOPTIMAL RESPONSE TO IMATINIB: A SINGLE CENTRE EXPERIENCE
Ferrero, D.
Crisa, E.
Cerrano, M.
Pirillo, F.
Riccomagno, P.
Nicolosi, M.
Boccadoro, M.
Vitolo, U.
Pregno, P.
HAEMATOLOGICA, 2012, 97 : 539 - 539
[37] ASCIMINIB, A NEW THERAPEUTIC OPTION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Garcia-Gutierrez, V
Boque Genovard, C.
Velez Tenza, P.
Giraldo, P.
Ramirez, M. J.
Alonso-Dominguez, J. M.
Jimenez Velasco, A.
de Abia, Luna A.
Hernadez-Boluda, J. C.
HAEMATOLOGICA, 2019, 104 : 302 - 303
[38] Platelet function in patients with chronic myeloid leukemia treated with asciminib
Nesr, George
Laffan, Mike
Claudiani, Simone
Innes, Andrew
Apperley, Jane
Milojkovic, Dragana
LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 3021 - 3023
[39] MANAGEMENT OF PONATINIB DOSING IN CHRONIC MYELOID LEUKEMIA PATIENTS
Sacha, T.
Szczepanek, E.
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, 72 (03): : 321 - 327
[40] Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations
Curik, Nikola
Laznicka, Adam
Polivkova, Vaclava
Krizkova, Jitka
Pokorna, Eva
Semerak, Pavel
Suchankova, Pavla
Burda, Pavel
Hochhaus, Andreas
Polakova, Katerina Machova
LEUKEMIA, 2024, 38 (06) : 1415 - 1418

← 1 2 3 4 5 →